fatigue; myalgia; peripheral neuropathy; this spontaneous report received from a consumer by a regulatory authority (nl-lrb-00740693) on 22-feb-2022 concerned a 53 year old female of unspecified race and ethnicity. the patient's weight was 81 kilograms, and height was 174 centimeters. the patient's past medical history included: covid-19. the patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 21c11-02 expiry: unknown) 1 dosage forms, 1 total (first dose) administered on 30-may-2021 for covid-19 immunisation. no concomitant medications were reported. on 30-jun-2021, the patient experienced fatigue, myalgia, and peripheral neuropathy. on 26-dec-2021, laboratory data included: sars-cov-2 test (severe acute respiratory syndrome) positive (nr: not provided) positive. the action taken with covid-19 vaccine ad26.cov2.s was not applicable. the patient had not recovered from fatigue, myalgia, and peripheral neuropathy. this report was serious (other medically important condition)

test date: 20211226; test name: sars-cov-2 test positive; result unstructured data: positive

na

na